1. Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study. (December 2019) Authors: Adamo, Vincenzo; Ricciardi, Giuseppina Rosaria Rita; Giuffrida, Dario; Scandurra, Giuseppa; Russo, Antonio; Blasi, Livio; Spadaro, Pietro; Iacono, Carmelo; Soto Parra, Hector J.; Savarino, Antonino; Ferraú, Francesco; Zerilli, Filippo; Verderame, Francesco; Butera, Alfredo; Santangelo, Carlo; Fra... Journal: Therapeutic advances in medical oncology Issue: Volume 11(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗